Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Sees Large Drop in Short Interest

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the target of a large drop in short interest in March. As of March 13th, there was short interest totaling 45,179 shares, a drop of 38.8% from the February 26th total of 73,856 shares. Based on an average trading volume of 34,298 shares, the short-interest ratio is currently 1.3 days. Approximately 0.3% of the company’s stock are short sold.

Genenta Science Price Performance

GNTA traded down $0.12 on Friday, reaching $0.71. The company had a trading volume of 1,159,284 shares, compared to its average volume of 57,574. Genenta Science has a 1 year low of $0.59 and a 1 year high of $10.00. The stock has a 50-day moving average price of $0.95 and a 200-day moving average price of $1.85.

Institutional Trading of Genenta Science

Institutional investors and hedge funds have recently made changes to their positions in the company. SmartHarvest Portfolios LLC purchased a new position in Genenta Science during the 4th quarter worth approximately $26,000. Citadel Advisors LLC purchased a new stake in Genenta Science in the third quarter valued at approximately $41,000. Alyeska Investment Group L.P. purchased a new stake in Genenta Science in the fourth quarter valued at approximately $328,000. Norges Bank acquired a new stake in shares of Genenta Science in the fourth quarter valued at approximately $337,000. Finally, Weiss Asset Management LP acquired a new stake in shares of Genenta Science in the fourth quarter valued at approximately $480,000. 15.13% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genenta Science in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.